How to Get Vyleesi (Bremelanotide) in Indiana

Who Can Prescribe Vyleesi in Indiana

Any Indiana-licensed physician (MD or DO), nurse practitioner with full prescriptive authority, or physician assistant operating under a collaborative agreement can write a Vyleesi prescription. Indiana granted NPs full practice authority in 2024, meaning NPs no longer require a supervising physician to prescribe schedule-unscheduled medications like bremelanotide. PAs still need a collaborative agreement with a physician, but that agreement does not restrict the specific drugs a PA may prescribe as long as the medication falls within the PA's scope.

Bremelanotide is not a controlled substance. It carries no DEA scheduling, so there are no triplicate-prescription or quantity-limit barriers at the state pharmacy board level. The primary requirement is that the prescriber documents an HSDD diagnosis consistent with DSM-5 criteria: persistently reduced or absent sexual desire causing marked distress, not explained by another mental disorder, relationship factors, medication effects, or a general medical condition.

Specialists who most commonly prescribe Vyleesi include gynecologists, sexual medicine physicians, psychiatrists comfortable with sexual dysfunction, and primary care providers with an interest in women's health. If your current provider is unfamiliar with bremelanotide, a telehealth consultation may be the fastest path to evaluation.

Getting Vyleesi Through Telehealth in Indiana

Indiana law allows synchronous audio-video telehealth visits to establish a provider-patient relationship and issue new prescriptions. A telehealth provider licensed in Indiana can evaluate HSDD symptoms, review your medical history, order baseline labs, and prescribe bremelanotide without an in-person visit. This makes access practical for patients in rural counties where no local provider has experience with Vyleesi.

The RECONNECT phase 3 trial (N=1,247) established bremelanotide's efficacy: patients self-administering 1.75 mg subcutaneously reported a statistically significant increase in desire (measured by the Female Sexual Function Index desire domain) and a significant decrease in distress (measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm) compared with placebo over 24 weeks. These are the trial data most prescribers reference when making a clinical determination.

During a telehealth visit, expect the provider to screen for cardiovascular risk factors. The FDA prescribing information warns that bremelanotide can cause transient blood pressure increases of approximately 6 mmHg systolic and 3 mmHg diastolic, typically resolving within 12 hours. Patients with uncontrolled hypertension or known cardiovascular disease are not candidates. A blood pressure reading (even a home cuff reading shared during the telehealth visit) is the minimum cardiovascular screen most providers will accept.

Telehealth platforms that operate in Indiana typically ship the autoinjector or coordinate with a specialty pharmacy to deliver the medication to the patient's home. Turnaround from visit to delivery usually falls between 5 and 10 business days, depending on pharmacy processing and insurance verification.

What Labs and Evaluations Are Needed Before Prescribing

Bremelanotide does not require an extensive laboratory workup, but most prescribers order a focused panel to rule out organic causes of low desire and to confirm the patient is an appropriate candidate.

A standard pre-prescription evaluation includes a blood pressure check, thyroid-stimulating hormone (TSH) level, and a basic hormonal panel (estradiol, total testosterone, and sex hormone-binding globulin). The Endocrine Society's clinical practice guideline on female sexual dysfunction recommends checking testosterone and thyroid function before attributing low desire solely to HSDD, since hypothyroidism and androgen deficiency can both present with diminished libido.

A complete blood count and comprehensive metabolic panel are sometimes added to establish baseline organ function, particularly hepatic function, because bremelanotide is metabolized hepatically. The FDA label does not require liver function testing, but some providers include it as a precaution in patients taking multiple hepatically cleared medications.

A pregnancy test is standard. Bremelanotide is contraindicated in pregnancy (FDA Pregnancy Category N/A under the post-2015 labeling system, but animal studies showed embryo-fetal toxicity). Providers will confirm a reliable contraception method before prescribing. The FDA label specifically states that women should use effective contraception during treatment.

Melanin monitoring is another consideration unique to this drug. Bremelanotide is a melanocortin-4 receptor agonist that can cause focal hyperpigmentation, particularly on the face, gingiva, and breasts. The FDA label advises that patients with dark skin may find these changes harder to detect. No lab test monitors for this effect. Providers rely on patient self-report and visual inspection.

Pharmacy Access and 503A Compounding in Indiana

Once prescribed, patients have two main pharmacy pathways. The first is the brand-name Vyleesi autoinjector (1.75 mg/dose), available through retail and specialty pharmacies. Major chains like CVS, Walgreens, and Kroger pharmacies in Indiana can order and dispense Vyleesi, though it is not routinely stocked on shelves. Most pharmacies require 2 to 5 business days to obtain the product from their wholesaler.

The second pathway is a 503A compounding pharmacy. Indiana's Board of Pharmacy licenses 503A compounding facilities that can prepare bremelanotide for individual patients with a valid prescription. Compounded bremelanotide is typically supplied as a multi-use vial with syringes rather than the single-use autoinjector format, and it generally costs less than the brand-name product. Patients should confirm that the compounding pharmacy holds a current Indiana Board of Pharmacy license and that the prescriber writes the prescription specifically for compounded bremelanotide if that is the intended route.

503A pharmacies in Indiana can ship compounded bremelanotide within the state. For out-of-state 503A pharmacies shipping into Indiana, the pharmacy must hold a nonresident pharmacy license issued by the Indiana Board of Pharmacy. Patients receiving shipments should verify cold-chain handling, as bremelanotide solution requires controlled temperature storage (20 to 25°C for the branded product, per the FDA label).

Specialty pharmacies affiliated with telehealth platforms often handle the entire fulfillment process, including insurance verification, prior authorization support, and direct-to-patient shipping. This removes much of the logistical burden from the patient.

Insurance Coverage and Prior Authorization in Indiana

Commercial insurance plans in Indiana vary widely in their coverage of Vyleesi. Some plans include it on formulary with prior authorization. Others classify it as a lifestyle drug and exclude it entirely. The average wholesale price for Vyleesi is approximately $950 for a package of four autoinjectors (four doses), making insurance coverage a significant financial consideration.

Indiana Medicaid does not cover Vyleesi. The state's preferred drug list excludes bremelanotide, and no exception process is currently published for HSDD medications under the Indiana Health Coverage Programs formulary. Patients on Medicaid who want to try bremelanotide will need to pay out of pocket or use a compounded formulation, which typically ranges from $100 to $300 per month depending on dosing frequency.

For commercially insured patients, prior authorization typically requires the following documentation:

• A confirmed DSM-5 diagnosis of HSDD in a premenopausal woman
• Documentation that the low desire is not attributable to a co-existing medical or psychiatric condition, relationship factors, or medication side effects
• Confirmation that the patient has tried or has a contraindication to flibanserin (Addyi), the only other FDA-approved HSDD treatment, since many payers require step therapy through an oral agent before approving an injectable
• A blood pressure reading confirming the absence of uncontrolled hypertension
• A statement from the prescriber that the patient is not pregnant and is using reliable contraception

The American College of Obstetricians and Gynecologists supports pharmacologic treatment of HSDD when behavioral and psychosocial interventions have been considered. Including a reference to ACOG's position in the prior authorization letter can strengthen the clinical justification.

Prior authorization decisions in Indiana typically take 3 to 5 business days for commercial plans. If denied, patients have the right to an expedited appeal, which Indiana law requires plans to resolve within 72 hours for urgent requests.

Transferring a Vyleesi Prescription to Indiana

Patients relocating to Indiana or visiting from another state can transfer an existing Vyleesi prescription. Indiana accepts prescription transfers from any U.S. state for non-controlled medications. The receiving pharmacy contacts the originating pharmacy to verify and transfer the prescription record. This process usually takes 24 to 48 hours.

If the original prescription was issued by a provider not licensed in Indiana, the patient will eventually need to establish care with an Indiana-licensed prescriber for ongoing refills. Telehealth makes this straightforward. A single virtual visit can re-establish the prescribing relationship under Indiana licensure.

For patients using a mail-order or specialty pharmacy, verify that the pharmacy holds a nonresident license with the Indiana Board of Pharmacy. Prescriptions shipped into Indiana from an unlicensed out-of-state pharmacy violate state law, and pharmacists may refuse to process them.

Clinical Considerations Specific to Indiana Patients

Indiana has a higher-than-national-average prevalence of obesity and cardiovascular disease, according to CDC BRFSS data. Because bremelanotide causes transient increases in blood pressure and can provoke nausea (reported in 40% of patients in the RECONNECT trial vs. 1% with placebo), prescribers in Indiana should pay particular attention to cardiovascular screening and antiemetic counseling.

Nausea is the most common reason for discontinuation. In RECONNECT, 13% of bremelanotide-treated patients discontinued due to nausea alone. Prophylactic ondansetron 4 mg taken 30 minutes before bremelanotide administration has been used off-label by some clinicians to mitigate this side effect, though no randomized trial has tested this strategy specifically. The nausea tends to diminish after the first few doses in many patients.

Bremelanotide should not be combined with naltrexone (used for alcohol use disorder and opioid use disorder), as the FDA label notes potential for decreased efficacy of both agents due to shared melanocortin receptor pathway involvement. Indiana has expanded naltrexone prescribing as part of its opioid crisis response. Prescribers should specifically ask about naltrexone use, including the extended-release injectable form (Vivitrol), before initiating bremelanotide.

The maximum recommended use is 8 doses per calendar month, with no more than 1 dose in any 24-hour period. Patients do not take bremelanotide daily. It is used on-demand, self-administered as a 1.75 mg subcutaneous injection into the abdomen or thigh approximately 45 minutes before anticipated sexual activity. In the RECONNECT trial, participants used a median of 4 to 5 doses per month. The FDA label does not restrict which days of the week the drug can be used, only the frequency cap.

Cost-Reduction Strategies for Indiana Patients

Brand-name Vyleesi carries a list price that puts it out of reach for uninsured patients without financial assistance. Several strategies can reduce the cost:

Manufacturer copay cards from Cosette Pharmaceuticals may reduce out-of-pocket costs for commercially insured patients to as low as $0 to $50 per fill, depending on plan structure. These cards do not apply to government-funded insurance (Medicaid, Medicare, Tricare).

Compounded bremelanotide from a licensed 503A pharmacy typically costs $100 to $300 per month, depending on concentration, vial size, and the number of doses prescribed. This is the most common cost-reduction path for uninsured or underinsured patients in Indiana.

Patient assistance programs may be available through the manufacturer for patients who meet income eligibility criteria. Checking the Cosette Pharmaceuticals website or calling their patient support line is the starting point.

Some telehealth platforms bundle the consultation fee and medication cost into a single monthly price, which can simplify budgeting and reduce total cost compared to separate provider visits and pharmacy fills.

Patients using compounded formulations should confirm the pharmacy's quality-control practices. The FDA guidance on 503A compounding specifies that 503A pharmacies must compound pursuant to a valid patient-specific prescription and comply with USP <797> sterile compounding standards for injectable preparations.